TP53 and cancer: Therefore, there is an urgent need to identify more general, clinically targetable biological mechanisms that exploit general cancer cell characteristics rather than the classically studied oncogenic driver genes that mediate them, such mutated APC, TP53 or RAS/MAPK5.